DSFIR logo

DSM-Firmenich AG Stock Price

ENXTAM:DSFIR Community·€23.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 61 Fair Values set on narratives written by author

DSFIR Share Price Performance

€93.38
11.16 (13.57%)
€115.35
Fair Value
€93.38
11.16 (13.57%)
19.0% undervalued intrinsic discount
€115.35
Fair Value
Price €93.38
AnalystHighTarget €115.35
AnalystConsensusTarget €79.37
AnalystLowTarget €60.56

DSFIR Community Narratives

·
Fair Value €115.35 19.0% undervalued intrinsic discount

Sustainability And Precision Nutrition Will Fuel Global Market Expansion

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value €79.37 17.7% overvalued intrinsic discount

DSFIR: Resilient Consumer Health Demand Will Drive Performance Amid Pricing Pressure

0users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
·
Fair Value €60.56 54.2% overvalued intrinsic discount

Regulatory And Merger Challenges Will Constrain Benefits But Spark Growth

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€79.37
17.7% overvalued intrinsic discount
Revenue
3.64% p.a.
Profit Margin
7.49%
Future PE
27.42x
Price in 2029
€94.41
€60.56
54.2% overvalued intrinsic discount
Revenue
2.44% p.a.
Profit Margin
5.27%
Future PE
30.82x
Price in 2029
€72.13

Trending Discussion

No trending discussion available.

Updated Narratives

DSFIR logo

DSFIR: Share Repurchase Program Will Drive Bullish Re Rating Potential

Fair Value: €115.35 19.0% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
DSFIR logo

DSFIR: Share Buyback And New Listing Plan Will Shape Future Re Rating

Fair Value: €79.37 17.7% overvalued intrinsic discount
28 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
DSFIR logo

DSFIR: Reset Profitability Expectations Will Pressure Future Margin Resilience

Fair Value: €60.56 54.2% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with moderate growth potential.

2 Risks
2 Rewards

DSM-Firmenich AG Key Details

€9.1b

Revenue

€5.5b

Cost of Revenue

€3.5b

Gross Profit

€3.2b

Other Expenses

€324.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.31
39.18%
3.58%
37.6%
View Full Analysis

About DSFIR

Founded
1902
Employees
20786
CEO
Dimitri de Vreeze
WebsiteView website
www.dsm-firmenich.com

DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.

Recent DSFIR News & Updates

Narrative Update Jul 22

DSFIR: Share Repurchase Program Will Drive Bullish Re Rating Potential

The analyst price target for DSM-Firmenich has been raised from €103 to about €115. Analysts point to slightly higher assumed revenue growth, a modestly stronger profit margin profile, and a higher future P/E assumption as key drivers of the revised valuation.

Recent updates

No updates